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Studies have shown that low forced vital capacity (LFVC) is associated with atherosclerosis. However, it is unclear whether
LFVC is associated with resting electrocardiographic ST-T abnormalities, a common ﬁnding that is prognostic for cardiovascular
events. Therefore, pulmonary functions, ST-T abnormalities deﬁned with Minnesota Code, and cardiometabolic risk factors were
examined in a cross-sectional study of 1,653 asymptomatic adults without past history of coronary heart diseases. The prevalence
of diabetes, metabolic syndrome, and ST-T abnormalities signiﬁcantly increased with decreasing percent of predicted forced vital
capacity (%PFVC). ST-T abnormalities were observed in 73 subjects (4.4% in total). Multiple logistic regression analysis showed
that, compared with the highest quartile of %PFVC (≥99.7%), the lowest quartile of %PFVC (≤84.2%) was persistently associated
with ST-T abnormalities even after further adjustment for diabetes or metabolic syndrome (odds ratio (95%CI): 2.44 (1.16–
5.14) and 2.42 (1.15–5.10), resp.). Similar trends were observed when subjects were divided into quartiles according to percent of
predicted forced expiratory volume in 1 second (FEV1), but not the ratio of FEV1/FVC. In conclusion, LFVC may be associated
with ST-T abnormalities independent of metabolic abnormalities in asymptomatic adults, suggesting a plausible link between
impaired pulmonary defects and cardiovascular diseases.
1.Introduction
Accumulating evidence has shown that not only impaired
obstructive pulmonary function but also low forced vital
capacity (LFVC) and impaired restrictive pulmonary func-
tion are associated with increased risk of mortality, partially
owing to cardiovascular disease [1, 2]. Some studies have
shown that LFVC is associated with arterial stiﬀness assessed
by pulse-wave velocity [3, 4] and coronary artery calciﬁ-
cation [5], which may reﬂect systemic atherosclerosis. In
addition, LFVC and a restrictive pattern have been associated
with critical metabolic abnormalities such as type 2 diabetes
and metabolic syndrome (MetS) [2, 5–8], which are often
followed by the development of cardiovascular disease [9,
10]. To date, however, the association between and the
underlying mechanism of such pulmonary function defects
and subclinical cardiovascular disease have been poorly
understood.
Meanwhile, ST depression, T-wave abnormalities, or
both (ST-T abnormalities), particularly minor ST-T abnor-
malities, on the resting electrocardiogram are commonly
observed in the general population without coronary heart
disease [11–15]. Major ST-T abnormalities are an indepen-
dent predictor for stroke [13], cardiovascular events, and
increased mortality risk in people without heart disease
at baseline [11, 12]. Likewise, many studies have provided
evidence that even minor ST-T abnormalities are associated
with increased risk for future cardiovascular disease inde-
pendent of traditional risk factors [14, 16, 17], although the
prognostic signiﬁcance of minor ST-T abnormalities has not
been well established [14].
In the light of this evidence, we hypothesized that
impaired pulmonary functions, especially LFVC, may be
associated with ST-T abnormalities irrespective of car-
diometabolic risk factors, diabetes, and MetS. So far, no
large epidemiological studies have examined the associations2 Pulmonary Medicine
between impaired lung functions and ST-T abnormalities in
asymptomatic individuals without overt heart disease.
Therefore, we examined lung functions, ST-T abnormal-
ities that comprised major and minor ST-T abnormalities,
cardiometabolic risk factors, diabetes, and MetS in a cross-
sectional study of asymptomatic adults who underwent an
annual checkup. Abnormal pulmonary function was evalu-
ated by continuous pulmonary function variables including
the percentage of predicted forced vital capacity (%PFVC).
2. Methods
The current study represents a series of studies performed in
collaborationwithJosaiUniversity,Sakado,Japan,andSocial
Insurance Omiya General Hospital, Saitama, Japan, that
were conducted to explore the causalities and mechanism in
lifestyle-related diseases. The study design and protocol have
been described elsewhere [8] .T h ep r o t o c o lw a sa p p r o v e db y
the Ethical Committee of Josai University and the Council
of the Hospital, and informed consent was obtained from all
participants.
3.Subjects
Asymptomatic healthy subjects (n = 2,488) were randomly
recruited from those who underwent complete medical
checkupsattheirownwillattheHealthCareCenterattached
to Omiya General Hospital between April 2009 and March
2010. Most lived or worked close to the hospital (a small por-
tion was treated in the hospital). Individuals who required
immediate treatment for suspected cancers, pneumothorax,
or infectious pneumonia, including tuberculosis, were not
included from the beginning. All recruited subjects, who
were free from overt disability and hemiplegia, completed
a questionnaire about their lifestyle characteristics. Exclu-
sion criteria of subjects and a ﬂow chart are shown in
Figure 1. Since people less than 45 years old are less likely
to have ST-T abnormalities, ﬁrst, subjects outside the age
limitation of 45 to 80 years were excluded. Second, subjects
with a high C-reactive protein (CRP) level (>10mg/L) were
excluded because of latent critical diseases or inﬂammation.
Third, subjects with abnormal electrocardiograms, with the
exception of ST-T abnormalities, were excluded. Subjects
with a self-reported medical history of overt coronary heart
disease were also excluded. Finally, after additional exclusion
of subjects with suspected interstitial pneumonia based on
chest X-ray ﬁndings and those without available spirometry
data, 1,653 subjects (1,014 men and 639 women) were
eligible for this analysis.
4. Laboratory Measurements and
Determinationof MetSandDiabetes
Anthropometric measurements and laboratory tests were
carried out after an overnight fast. Waist circumference was
measured at the height of the navel. Clinical and biochem-
ical variables were measured automatically with standard
methods using an autoanalyzer (Hitachi, Tokyo, Japan). The
diagnosis of MetS was based on the modiﬁed Third Report
of the National Cholesterol Education Program Expert
Panel/Adult Treatment Panel criteria [9] with the following
cutoﬀ values: (1) systolic blood pressure of ≥130mmHg and
diastolic blood pressure of ≥85mmHg; (2) triglycerides of
≥150mg/dL; (3) low high-density lipoprotein of <40mg/dL
for men and <50mg/dL for women; (4) fasting plasma
glucose of ≥100mg/dL; (5) waist circumference of ≥90cm
for men and ≥80cm for women. We took ethnic-speciﬁc
values for waist circumference into consideration. MetS was
diagnosedinsubjectsfulﬁllingthreeormoreoftheaboveﬁve
criteria. Subjects receiving medication for any of these com-
ponentsweredeﬁnedashavingthecomponent.Diabeteswas
deﬁned as a fasting plasma glucose of ≥126mg/dL or HbA1c
of ≥6.5% according to the American Diabetes Association
criteria [18], or treatment with oral hypoglycemic drugs or
insulin. HbA1c was converted to National Glycohemoglobin
Standardization Program (NGSP) levels by the formula
HbA1c (%) (NGSP) = HbA1c (JDS) (%) + 0.4% [19].
5.Spirometry
Pulmonary function tests were performed with a spirometry
analyzer (Autospiro-507, Minato Medical Science Co., Ltd.,
Osaka,Japan).Thetestwasperformedbytrainedtechnicians
with the subject in a standing position. The %PFVC,
percentageofpredictedforcedexpiratoryvolumein1second
(%PFEV1),andratioofforcedexpiratoryvolumein1second
toobservedforcedvitalcapacity(FEV1/FVC)werecalculated
as in our previous report [8]. We quoted the standard
predicted values for FVC, FEV1,a n dF E V 1/FVC from data
published by the Japanese Respiratory Society in 2001 [20].
6.Electrocardiogram
Standard 12-lead electrocardiograms were recorded with
an electrocardiogram recorder (Cardio Base FDX-4521,
Fukuda Denshi Co., Ltd., Tokyo, Japan). ST-T abnormalities
were deﬁned with the Minnesota Code [21]. Minor ST-T
abnormalitiesincludedthefollowing:STjunctiondepression
of <0.5mm (MC 4-3); ST junction depression of >1mm
and ST segment ascent, that is, upslope (MC 4-4); T wave
ﬂat, diphasic, or inverted by <1mm (MC 5-3). Major ST-T
abnormalities included (MC 4-1), (MC 4-2), (MC 5-1), and
(MC 5-2). The ﬁndings were ﬁrst determined by experienced
physicians and subsequently conﬁrmed by trained medical
laboratory technicians, all of whom exclusively belong to
the Social Insurance Omiya General Hospital and were
blinded to individuals’ data. The minor and major ST-T
abnormalities were combined and analyzed together in this
study because, on the checkup sheets, minor and major ST
abnormalities were recorded together indistinguishably.
7.StatisticalAnalysis
Data are expressed as means ± SD or median/geometric
mean (interquartile range). Subjects were divided into quar-
tiles according to continuous pulmonary function variables:Pulmonary Medicine 3
2488 subjects underwent detailed 
medical checkups between April 
2009 and March 2010
65 subjects were excluded because 
of self-reported past histories
 of heart disease (angina, 
myocardial infarction, etc.)
4 subjects were excluded because 
they did not undergo spirometry 
(lack of data)
1653 subjects aged 45 to 80 
years remained for this analysis
3 subjects were excluded because 
of suspected interstitial pneumonia
96 subjects were excluded because of 
Complete bundle branch block (n = 52)
Left ventricular hypertrophy (n = 31)
Abnormal Q wave (n = 6)
Wolff-Parkinson-White syndrome (n = 4)
Bradycardia (< 40 bpm) (n = 2)
Second-degree atrioventricular block (n = 2)
(some of these overlapped one another)
the following ECG abnormalities:
Atrial ﬁbrillation (n = 17 )
26 subjects with high serum
excluded because of latent disease
613 younger subjects (< 45 years old)
and 28 old subjects (> 80 years old)
were excluded
C-reactive protein (> 10 mg/L) were
Figure 1: Exclusion criteria of subjects and ﬂow chart.
%PFVC, %PFEV1,a n dF E V 1/FVC. P values for continuous
variables and categorical variables were determined with
ANOVA and the χ2-test, respectively.
Multivariate logistic regression models were used to
examine the associations between the lowest quartiles (Q1)
of lung functions and ST-T abnormalities compared with
the corresponding highest quartiles (Q4), controlling for
clinical confounding factors including diabetes and MetS.
This analysis yielded odds ratios (OR) and 95% conﬁdential
intervals (95% CI). Tests for linear trends (P for trend) were
calculated by treating quartile categories (Q1–Q4) as a con-
tinuous variable (i.e., 1–4), and the same model analysis was
conducted. In this study, hypertension (≥130/85mmHg)
was considered as a special confounder that substantially
interferes with the associations because hypertension is likely
to aﬀect ST-T abnormalities and the decline of FVC [13,
22]. Statistical analyses were performed using SPSS software
version 18.0 (SPSS-IBM, Chicago, IL) and Statview version
5.0 (SAS Institute, Cary, NC). Values of P<0.05 were
considered to be statistically signiﬁcant.
8. Results
Overall, most subjects in this study had relatively good pro-
ﬁlesintermsofanthropometricandbiochemicalparameters,
including pulmonary functions tests (Table 1). The preva-
lence of cardiometabolic risk factors, diabetes, MetS, and
ST-T abnormalities signiﬁcantly increased with decreasing
%PFVC (toward Q4).
Multiple logistic analysis showed that compared with
the highest quartile of %PFVC (≥99.7%) (Q1), the lowest
quartile (≤84.2%) (Q4) was signiﬁcantly associated with
ST-T abnormalities (Table 2). This association remained
signiﬁcant even after adjustment for age, sex, smoking,
alcohol consumption, frequency of exercise, self-reported
past history of stroke, waist circumference, and CRP (both
as a continuous variable), with signiﬁcant P for trends.
Moreover, extended adjustment for diabetes (Model 4) or
MetS (Model 5) attenuated but did not remarkably alter the
associations. In these conditions, diabetes and MetS were
signiﬁcantly associated with ST-T abnormalities (OR (95%
CI), 2.18 (1.18–4.03), P = 0.01 and 2.20 (1.23–3.93), P =
0.008, resp.; data not shown).
Likewise, similar trends were observed when subjects
were divided into quartiles according to %PFEV1.H o w e v e r ,
observed associations between lowest quartile of %PFEV1
andST-Tabnormalitieswerenotsigniﬁcantafteradjustment
for diabetes or MetS. In contrast, no signiﬁcant associations
between lowest quartile of FEV1/FVC and ST-T abnormali-
ties were observed in comparison with the highest quartile of
FEV1/FVC, irrespective of adjustments for confounders.
Meanwhile, the lowest quartile of %PFVC was sig-
niﬁcantly associated with hypertension (≥130/85mmHg)
(OR (95%CI), 1.76 (1.30–2.38), P = 0.0003, data not
shown) compared with the highest quartile, even after
full adjustments for confounders in Model 3 of Table 2.
However, the signiﬁcant association between LFVC and
ST-T abnormalities persisted after further adjustments for
confounders in Model 3 of Table 2, plus hypertension or
medicationforhypertension(OR(95%CI),2.43(1.15–5.11),
P = 0.02 and 2.58 (1.23–5.40), P = 0.01, resp., data not
shown).4 Pulmonary Medicine
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Table 2: Odds ratio (95% CI) of lung function quartiles for ST-T abnormalities.
Q1
(highest) Q2 Q3 Q4 (lowest) P for trend∗
%PFVC, n 412 413 414 414
Model 1 1 1.19 (0.52–2.68) 1.66 (0.77–3.55) 2.95 (1.46–5.95)† 0.0007
Model 2 1 1.33 (0.59–3.03) 1.83 (0.85–3.95) 3.27 (1.60–6.69)† 0.0004
Model 3 1 1.30 (0.56–3.00) 1.74 (0.79–3.81) 2.59 (1.23–5.42)§ 0.006
Model 4 1 1.29 (0.56–2.97) 1.74 (0.79–3.83) 2.44 (1.16–5.14)§ 0.009
Model 5 1 1.29 (0.56–3.00) 1.69 (0.77–3.73) 2.42 (1.15–5.10)§ 0.01
%PFEV1, n 412 415 414 412
Model 1 1 0.67 (0.31–1.47) 1.06 (0.53–2.13) 1.87 (1.002–3.51)§ 0.02
Model 2 1 0.78 (0.36–1.72) 1.35 (0.66–2.77) 2.42 (1.23–4.75)§ 0.003
Model 3 1 0.76 (0.34–1.69) 1.16 (0.56–2.42) 2.09 (1.04–4.21)§ 0.02
Model 4 1 0.75 (0.34–1.69) 1.10 (0.53–2.31) 2.00 (0.99–4.0.4) 0.02
Model 5 1 0.76 (0.34–1.70) 1.13 (0.54–2.35) 2.00 (0.99–4.06) 0.02
FEV1/FVC, n 412 413 416 412
Model 1 1 1.41 (0.76–2.63) 0.71 (0.34–1.46) 0.94 (0.48–1.86) 0.42
Model 2 1 1.38 (0.74–2.59) 0.60 (0.28–1.26) 0.74 (0.36–1.56) 0.15
Model 3 1 1.56 (0.82–2.98) 0.69 (0.32–1.48) 0.94 (0.44–1.98) 0.41
Model 4 1 1.52 (0.80–2.91) 0.69 (0.32–1.49) 0.94 (0.44–1.98) 0.42
Model 5 1 1.55 (0.81–2.97) 0.69 (0.32–1.50) 0.93 (0.44–1.97) 0.41
Data are expressed as odds ratio (95% conﬁdence interval) with references of highest quartiles (Q1).
Model 1: unadjusted; Model 2: adjusted for age, sex, height, and current smoking (versus nonsmokers); Model 3: Model 2 plus adjustment for daily alcohol
consumption (versus infrequent/no alcohol consumption), regular exercise (versus no regular exercise), waist circumference, log-transformed CRP, and self-
reported past history of stroke; Model 4: Model 3 plus adjustment for diabetes; Model 5: Model 3 plus adjustment for MetS.
∗P values correspond to tests for linear trends across quartile treated as a continuous value.
†P<0.005, §P<0.0 5f o re a c ha s s o c i a t i o n .
9. Discussion
This study was conducted to investigate the relationship of
impaired lung functions with resting electrocardiographic
ST-T abnormalities in a cross-sectional analysis of asymp-
tomatic adults without past history of heart disease. We
found that LFVC and probably low FEV1,b u tn o tl o w
FEV1/FVC, were signiﬁcantly associated with ST-T abnor-
malities, which was attenuated by further adjustment for
cardiometabolic risk factors, diabetes (presumably mostly
type 2 diabetes in this study), or MetS, but remained
signiﬁcant. Notably, cardiometabolic risk factors included
circulating CRP and waist circumference, surrogate markers
of systemic inﬂammation, and amount of abdominal fat,
respectively. Collectively, the current ﬁndings suggest that
LFVC, which often reﬂects restrictive pulmonary function
pattern, may be independently associated with ST-T abnor-
malities irrespective of clinical confounders, diabetes, and
MetS, whereas obstructive pulmonary function defects are
not.
So far, no clinical study has examined the relationship
of LFVC with electrocardiographic abnormalities with the
exception of a study by Sideris and Katsadoros [23]. This
study reported a negative correlation between vital capacity
and number of abnormalities, such as a rightward shift of
the P-wave and clockwise rotation of QRS, but it did not
address ST or T-wave abnormalities. Thus, to our knowl-
edge, this study is the ﬁrst to demonstrate the association
between LFVC and ST-T abnormalities, which is conceivably
prognostic for cardiovascular events in asymptomatic people
[14, 16, 17].
According to previous studies, LFVC and restrictive
pulmonary defects have been associated with coronary
artery calciﬁcation [5] and arterial stiﬀness [3, 4]. Because
artery calciﬁcation and arterial stiﬀness generally reﬂect
atherosclerosis and ischemic cardiovascular diseases, the
current results are consistent with these previous studies.
Generally, ST-T abnormalities are observed in various con-
ditions,suchasischemia,hypokalemia,cardiomyopathy,and
pulmonary embolism [15]. Ohira et al. [13] mentioned that
minor ST-T abnormalities may reﬂect an end-organ eﬀect
of long-term hypertension because hypertensive men with
minor ST-T abnormalities tended to have longer durations
of hypertension in their study. Indeed, arterial stiﬀness
assessed with pulse-wave velocity is substantially aﬀected by
hypertension [24]. Furthermore, a recent study showed that
decline in FVC predicted incident hypertension in young
apparently healthy individuals [22]. Actually, in our study,
LFVC was robustly associated with hypertension, even after
full adjustments for critical confounders. Nevertheless, the
signiﬁcant association between LFVC and ST-T abnormali-
ties persisted after further adjustments for confounders plus
hypertension or medication for hypertension. Therefore,
although hypertension likely contributes in part to the
observed associations through the close interrelationship of
lung with cardiovascular system, other unknown factors may6 Pulmonary Medicine
principally interfere with the associations between LFVC and
ST-T abnormalities.
Considering that LFVC was associated with ST-T abnor-
malities independently of cardiometabolic factors, circulat-
ing CRP, diabetes, and MetS, which are proatherosclerotic
and proinﬂammatory [9, 10], several factors not examined
in this study, such as insulin resistance, oxidative stress, or
subclinical hypoxia, might interfere with the relationship
between LFVC and ST-T abnormalities. In accordance
with this, previous studies have hypothesized that insulin
resistance is a fundamental element for the pathophysiology
of LFVC and restrictive lung function [2, 6, 7].
Meanwhile, many studies in the past decade have shown
that a predisposition for cardiovascular disease and impaired
pulmonary functions (low vital capacity and low FEV1)a r e
associated with low birth weight [25, 26], possibly via phys-
iological alterations such as increased adrenocortical and
sympathoadrenal responses to an adverse fetal environment
[27].LFVCandST-Tabnormalitiesmightthenrelatetosuch
potential factors as epiphenomena.
Alternatively, physicochemical factors might interfere
with the associations. Of note, the American Heart Asso-
ciation recently updated its scientiﬁc statement to describe
that exposure to particulate-matter air pollution contributes
to cardiovascular morbidity and mortality [28]. It high-
lighted several possible biological mechanisms secondary to
pulmonary oxidative stress, inﬂammation, and an impaired
lung autonomic nervous system that might result in vascu-
lar dysfunction and ST-segment depression irrespective of
metabolic abnormalities.
Several limitations should be mentioned. First, because
of the nature of cross-sectional studies, causality remains
unknown and must be elucidated in large prospective
studies. Second, it was not possible to distinguish between
major and minor ST-T abnormalities in this study because
the electrocardiogram ﬁndings on individual checkup sheets
in combinations of major and minor ST-T abnormalities
wererecordedtogetherindistinguishably.However,mostST-
T abnormalities were likely to be minor ST-T abnormal-
ities because the prevalence of minor ST-T abnormalities
is approximately 2-fold greater than that of major ST-T
abnormalities in the Japanese population [13].
Third, all subjects in this study were instructed by staﬀ
memberstrainedinspirometry,andthesubjectsperformeda
few rehearsals. Nevertheless, it was not clear whether all sub-
jects had acceptable results in the actual test, especially the
elderly, regardless of cognitive status, physical performance,
or education level. This is likely to result in potential bias of
the outcomes.
Finally, most subjects were healthy with good pro-
ﬁles in terms of various parameters, although a small
portion of them had several critical conditions such as
diabetes or history of stroke. Therefore, the current ﬁnd-
ings may not be applicable to other populations that
have more cardiometabolic risk factors and ST-T abnor-
malities, where the observed associations, if any, might
be dependent on hypertension, diabetes, or metabolic
syndrome.
10. Conclusion
LFVC may be associated with ST-T abnormalities indepen-
dently of cardiometabolic risk factors, diabetes, and MetS
in asymptomatic adults without overt heart disease. Our
results suggest that there is a mechanism linking low vital
capacity with common electrocardiographic abnormalities
and that this mechanism is prognostic for increased risk
for cardiovascular diseases, which needs to be conﬁrmed in
further larger studies.
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